68.41 0.00 (0.00%)
After hours: 6:50PM EDT
|Bid||65.80 x 1000|
|Ask||0.00 x 3200|
|Day's Range||67.76 - 68.57|
|52 Week Range||51.37 - 68.82|
|PE Ratio (TTM)||131.05|
|Earnings Date||Oct 16, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||1.12 (1.64%)|
|1y Target Est||71.31|
On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
About two months ago, grad student Azure Grant began wearing a glucose monitor every day. Diabetics have trouble regulating their glucose levels, and thus must track them closely. Here’s the catch: Grant doesn’t have diabetes.
On September 14, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x. Boston Scientific’s forward EV-to-EBITDA multiple is 19.1x, which is higher than the industry average of 16.7x. On September 14, Boston Scientific’s peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had forward PE multiples of 21.7x, 28.4x, and 18.3x, respectively.
BSX stock is trading ~53.0% higher than its 52-week low of $24.54 reported on December 6, 2017. Over the last week, BSX stock has risen ~4.5%. BSX stock has risen ~11.6% over the last month. Year-to-date, BSX stock has reported stellar gains of ~52.0%.
Abbott Laboratories (ABT) closed higher on the New York Stock Exchange on Sept. 13 after the board of directors declared a cash quarterly dividend of 28 cents. Warning! GuruFocus has detected 7 Warning Sign with ABT. Analysts expect 4% growth in the stock's market value, making Abbott Labs an appealing investment option.
Moody's Investors Service ("Moody's") today assigned Baa1 ratings to the senior unsecured notes to be offered by Abbott Ireland Financing DAC, a newly-formed financing subsidiary of Abbott Laboratories ("Abbott"). The outlook of Abbott Laboratories is positive. The rating outlook of Abbott Laboratories is positive.
ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 379 th consecutive quarterly ...
ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- For the sixth consecutive year, Abbott (ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries.
On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.
The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Indian government had in 2016 banned about 350 such drugs, referred to as fixed-dose combinations (FDCs), but the industry mounted various legal challenges that prompted the Supreme Court to call for a review by an advisory board. The president of the Indian Drug Manufacturers' Association, Deepnath Roychowdhury, said the order would have an impact on a market worth an estimated 16 billion rupees ($222 million) a year for such drugs, which are produced by both small and large pharmaceutical companies.
Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.
For this reason, some investors will resort to individual growth stocks. For example, dividend aristocrats, or stocks that have seen at least 25 consecutive years of dividend hikes, could bolster such a portfolio.
Can mood be decoded from brain data? The work is part of a larger movement aimed at developing better, more personalized therapies for psychiatric conditions like depression, anxiety, post-traumatic stress disorder and obsessive compulsive disorder using deep brain stimulation, a procedure that requires surgery and is highly invasive. The approach is similar to treatments already in use for movement disorders like Parkinson’s disease and epilepsy.
Since January 2, Boston Scientific’s (BSX) share price has risen 41.4%. The company posted 6% YoY (year-over-year) organic revenue growth in the first half of 2018. The company is thus expected to witness revenue growth rates in the second half similar to those it witnessed in the first half.
Hologic is a medical technology firm focused on developing solutions for women’s health. Year-to-date, Hologic stock is down ~9.6%. The event led to a ~4% decline in its stock price on August 13, when the announcement was made.
In September 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given Alexion stock a “buy” or higher rating, and two analysts have given Alexion a “hold” rating. The mean rating for Alexion stock is $1.83 with a target price of $158.41, implying an upside potential of 32.9% over Alexion’s closing price of $119.20 on September 4.
Livongo Health, a consumer digital health company is focused on the treatment of chronic diseases, is integrating its service with Abbott Labs' continuous glucose monitoring system. Livongo is about empowering people with chronic conditions live better and healthier lives, CEO Glen Tullman said on stage at Disrupt SF. Livongo started with a connected blood glucose monitor that captures data and sends it to the cloud, where it can be processed and analyzed. From here, Livongo delivers real-time insights to customers as well as their physician and even family members.